Outcomes following isolated right ventricular assist device as durable support for primary right heart failure: An INTERMACS analysis. Academic Article uri icon

Overview

abstract

  • Outcomes with isolated right ventricular assist devices (iRVAD) using pumps designed for the left ventricle are not well described. This study compares the clinical characteristics and outcomes of iRVAD patients to those patients treated with left ventricular assist device (LVAD) and biventricular assist devices (BiVAD). This study consisted of patients who received iRVAD from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) registry (2006-2017). The primary outcome was 2-year survival. Of 20,789 patients, 26 (0.13%) received iRVAD, 17 with pulsatile flow and 9 with continuous-flow devices. Device strategy was bridge to recovery/rescue therapy in 9 (35%), bridge to transplant/decision in 14 (52%), and destination therapy in 3 (12%). Twelve (46%) patients were INTERMACS profile 1, 5 patients (19%) required extracorporeal membrane oxygenation, and 13 (50%) needed mechanical ventilation. Two-year survival for patients with iRVAD (41.3%) was similar to BiVAD (45.2%) and significantly lower than LVAD (69.0%). In patients with isolated right-sided failure, long-term iRVAD support is feasible.

authors

  • Birati, Edo Y
  • Grandin, E Wilson
  • Zhang, Robert
  • Cabezas, Fausto
  • Rajagopal, Keshava
  • Seigerman, Matthew
  • Padegimas, Allison
  • Mazurek, Jeremy A
  • Kiernan, Michael S
  • Kapur, Navin K
  • Atluri, Pavan
  • Oliveira, Guilherme H
  • Pagani, Francis D
  • Myers, Susan L
  • Teuteberg, Jeffrey
  • Kormos, Robert L
  • Kirklin, James K
  • Acker, Michael A
  • Eduardo Rame, Jesus

publication date

  • April 1, 2025

Identity

PubMed Central ID

  • PMC12018192

Digital Object Identifier (DOI)

  • 10.1016/j.jhlto.2025.100258

PubMed ID

  • 40276318

Additional Document Info

volume

  • 8